Mirum Pharmaceuticals (NASDAQ:MIRM) Stock Price Expected to Rise, TD Cowen Analyst Says

Mirum Pharmaceuticals (NASDAQ:MIRM) had its price target raised by stock analysts at TD Cowen from $115.00 to $117.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. TD Cowen’s price target suggests a potential upside of 26.77% from the company’s current price.

Several other brokerages have also weighed in on MIRM. Weiss Ratings reissued a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a report on Thursday, January 22nd. Robert W. Baird raised their target price on Mirum Pharmaceuticals from $80.00 to $88.00 and gave the stock an “outperform” rating in a research report on Monday, December 8th. Leerink Partners lowered their price target on shares of Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating on the stock in a report on Thursday. Royal Bank Of Canada dropped their price objective on shares of Mirum Pharmaceuticals from $130.00 to $128.00 and set an “outperform” rating for the company in a research note on Thursday. Finally, Citigroup reiterated an “outperform” rating on shares of Mirum Pharmaceuticals in a research report on Friday, December 19th. One equities research analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $114.92.

Mirum Pharmaceuticals Stock Up 0.1%

Shares of MIRM opened at $92.29 on Thursday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 3.16 and a current ratio of 3.31. The company has a 50-day simple moving average of $93.40 and a 200-day simple moving average of $79.08. Mirum Pharmaceuticals has a 52 week low of $36.88 and a 52 week high of $109.28. The firm has a market capitalization of $4.74 billion, a P/E ratio of -192.27 and a beta of 0.49.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its earnings results on Wednesday, February 25th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.13). Mirum Pharmaceuticals had a negative return on equity of 8.98% and a negative net margin of 4.48%.The firm had revenue of $148.93 million for the quarter, compared to analyst estimates of $141.78 million. During the same period last year, the business earned $1.00 earnings per share. The firm’s quarterly revenue was up 49.8% compared to the same quarter last year. On average, equities research analysts expect that Mirum Pharmaceuticals will post -1.43 earnings per share for the current year.

Insider Buying and Selling at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, COO Peter Radovich sold 2,631 shares of the firm’s stock in a transaction dated Monday, February 2nd. The shares were sold at an average price of $103.30, for a total value of $271,782.30. Following the completion of the sale, the chief operating officer owned 20,655 shares in the company, valued at approximately $2,133,661.50. This trade represents a 11.30% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Eric Bjerkholt sold 1,053 shares of the business’s stock in a transaction dated Monday, January 26th. The stock was sold at an average price of $96.19, for a total transaction of $101,288.07. Following the completion of the transaction, the chief financial officer directly owned 43,741 shares of the company’s stock, valued at approximately $4,207,446.79. This represents a 2.35% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 45,136 shares of company stock worth $4,352,029 over the last 90 days. Company insiders own 14.36% of the company’s stock.

Institutional Trading of Mirum Pharmaceuticals

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. CWM LLC raised its position in Mirum Pharmaceuticals by 30.8% in the 3rd quarter. CWM LLC now owns 683 shares of the company’s stock worth $50,000 after purchasing an additional 161 shares during the last quarter. Legal & General Group Plc increased its stake in shares of Mirum Pharmaceuticals by 0.4% in the 2nd quarter. Legal & General Group Plc now owns 43,010 shares of the company’s stock valued at $2,189,000 after buying an additional 176 shares during the period. MCF Advisors LLC increased its stake in shares of Mirum Pharmaceuticals by 76.4% in the 3rd quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after buying an additional 185 shares during the period. Janney Montgomery Scott LLC raised its position in shares of Mirum Pharmaceuticals by 6.7% during the fourth quarter. Janney Montgomery Scott LLC now owns 3,200 shares of the company’s stock worth $253,000 after acquiring an additional 200 shares during the last quarter. Finally, Teacher Retirement System of Texas lifted its stake in shares of Mirum Pharmaceuticals by 2.2% during the second quarter. Teacher Retirement System of Texas now owns 9,903 shares of the company’s stock valued at $504,000 after acquiring an additional 215 shares during the period.

Mirum Pharmaceuticals News Summary

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Q4 revenue beat and strong product growth — Mirum reported ~50% year-over-year revenue growth driven by Livmarli and other drug sales, topping estimates and providing fundamental support for the stock. Mirum’s Q4 Earnings Lag, Higher Product Sales Drive Y/Y Revenues
• Positive Sentiment: Analyst upgrades/target raises — Stifel raised its price target to $125 (buy) and TD Cowen raised its target to $117 (buy), signaling continued analyst confidence and suggesting meaningful upside from current levels. Analyst Coverage (Benzinga)
• Neutral Sentiment: Analyst consensus roundup — several coverage notes were published (13-analyst roundup) that summarize mixed but generally constructive views; useful for gauging street positioning. 13 Analysts Have This To Say About Mirum Pharmaceuticals
• Neutral Sentiment: Other analyst moves — RBC and Citizens JPM trimmed targets modestly but kept outperform/market outperform ratings, indicating conviction despite small PT adjustments. RBC Commentary (Street Insider)
• Neutral Sentiment: Earnings call and transcripts available — management commentary from the Q4 call provides more detail on commercialization cadence and upcoming catalysts; worth reviewing for guidance tone and commercialization cadence. Q4 2025 Earnings Call Transcript (Fool)
• Negative Sentiment: EPS miss — Mirum reported a GAAP loss of ($0.11) vs. consensus of $0.02, a notable EPS miss that can weigh on sentiment despite the revenue beat. Mirum Reports Q4 Loss, Tops Revenue Estimates (Zacks)
• Negative Sentiment: Guidance mixed — management set FY2026 revenue guidance of $630–$650M vs. a consensus near $646M, leaving limited upside to Street expectations and creating potential downside if execution slips. Press Release / Guidance (Company PDF)
• Negative Sentiment: Short-term pullback coverage — commentary and retail pieces explaining intra-day/short-term weakness (e.g., articles on why MIRM was down) may amplify volatility even as fundamentals improve. Why MIRM Stock Is Down 13.46% (AAII)

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.